|
1.
|
|
12 p, 1.1 MB |
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL : primary analysis of the CAPTIVATE FD cohort
/
Tam, Constantine S (University of Melbourne) ;
Allan, John N (Weill Cornell Medicine) ;
Siddiqi, Tanya (City of Hope National Medical Center) ;
Kipps, Thomas J. (University of California San Diego) ;
Jacobs, Ryan (Levine Cancer Institute) ;
Opat, Stephen (Monash University) ;
Barr, Paul M. (University of Rochester Medical Center) ;
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ;
Trentin, Livio (University of Padova) ;
Bannerji, Rajat (Rutgers Cancer Institute of New Jersey) ;
Jackson, Sharon (Middlemore Hospital) ;
Kuss, Bryone J. (Flinders University and Medical Center) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Szafer-Glusman, Edith (Pharmacyclics LLC. an AbbVie Company) ;
Russell, Kristin (Pharmacyclics LLC. an AbbVie Company) ;
Zhou, Cathy (Pharmacyclics LLC. an AbbVie Company) ;
Ninomoto, Joi (Pharmacyclics LLC. an AbbVie Company) ;
Dean, James P. (Pharmacyclics LLC. an AbbVie Company) ;
Wierda, William G. (DepaUniversity of Texas MD Anderson Cancer Center) ;
Ghia, Paolo (IRCCS Ospedale San Raffaele) ;
Universitat Autònoma de Barcelona
CAPTIVATE (NCT02910583) is an international phase 2 study in patients aged ≤70 years with previously untreated chronic lymphocytic leukemia (CLL). Results from the cohort investigating fixed-duration (FD) treatment with ibrutinib plus venetoclax are reported. [...]
2022 -  10.1182/blood.2021014488
Blood, Vol. 139 Núm. 22 (february 2022) , p. 3278-3289
|
|
|
2.
|
|
17 p, 1.2 MB |
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes after Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study
/
Munir, Talha (St James's Hospital) ;
Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Owen, Carolyn (Tom Baker Cancer Centre) ;
Follows, George (Addenbrookes Hospital (Cambridge, Regne Unit)) ;
Benjamini, Ohad (Sheba Medical Center) ;
Janssens, Ann (UZ Leuven Gasthuisberg) ;
Levin, Mark-David (Albert Schweitzer Hospital) ;
Osterborg, Anders (Karolinska University Hospital and Karolinska Institutet (Suecia)) ;
Robak, Tadeusz (Medical University of Lodz. Copernicus Memorial Hospital) ;
Simkovic, Martin (University Hospital Hradec Kralove (República Txeca)) ;
Stevens, Don (Norton Cancer Institute) ;
Voloshin, Sergey (Russian Scientific and Research Institute of Hematology and Transfusiology) ;
Vorobyev, Vladimir (S.P. Botkin Moscow City Clinical Hospital) ;
Yagci, Munci (Gazi Universitesi Tip Fakultesi) ;
Ysebaert, Loic (Institut Universitaire du Cancer Toulouse Oncopole) ;
Qi, Keqin (Janssen Research & Development) ;
Qi, Qianya (Janssen Research & Development) ;
Parisi, Lori (Janssen Research & Development) ;
Srinivasan, Srinivasan (Oncology Translational Research. Janssen Research & Development) ;
Schuier, Natasha (Janssen Research & Development) ;
Baeten, Kurt (Janssen Research & Development) ;
Howes, Angela (Janssen Research & Development) ;
Caces, Donne Bennett (Janssen Research & Development) ;
Niemann, Carsten U (Rigshospitalet Copenhagen University Hospital) ;
Kater, Arnon P. (Amsterdam Medical Centers. University of Amsterdam)
PURPOSEIn GLOW, fixed-duration ibrutinib + venetoclax showed superior progression-free survival (PFS) versus chlorambucil + obinutuzumab in older/comorbid patients with previously untreated chronic lymphocytic leukemia (CLL). [...]
2023 - 10.1200/JCO.22.02283
Journal of Clinical Oncology, Vol. 41 Núm. 21 (20 2023) , p. 3689-3699
|
|
|
3.
|
|
|
4.
|
|
11 p, 1.9 MB |
Many people with chronic lymphocytic leukemia or small lymphocytic lymphoma benefit from ibrutinib treatment up to 8 years : a plain language summary
/
Barr, Paul M. (University of Rochester Medical Center, USA) ;
Owen, Carolyn (University of Calgary, Canada) ;
Robak, Tadeusz (Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland) ;
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy) ;
Bairey, Osnat (Rabin Medical Center, Petah Tikva, Israel) ;
Burger, Jan A (University of Texas MD Anderson Cancer Center, Houston, USA) ;
Hillmen, Peter (The Leeds Teaching Hospitals, St James Institute of Oncology, Leeds, UK) ;
Dearden, Claire (The Royal Marsden Hospital, London, UK) ;
Grosicki, Sebastian (Silesian Medical University, Katowice, Poland) ;
McCarthy, Helen (Royal Bournemouth General Hospital (Dorset, Regne Unit)) ;
Li, Jian Yong (Jiangsu Province Hospital, Nanjing, China) ;
Offner, Fritz (Universitair Ziekenhuis Gent, Belgium) ;
Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Jermain, Mandy (Pharmacyclics LLC, an AbbVie Company, South San Francisco, USA) ;
Zhou, Cathy (Pharmacyclics LLC, an AbbVie Company, South San Francisco, USA) ;
Hsu, Emily (Pharmacyclics LLC, an AbbVie Company, South San Francisco, USA) ;
Szoke, Anita (Pharmacyclics LLC, an AbbVie Company, South San Francisco, USA) ;
Kipps, Thomas J. (UCSD Moores Cancer Center, San Diego, USA) ;
Ghia, Paolo (Università Vita-Salute San Raffaele &IRCCS Ospedale San Raffaele, Milan, Italy)
What is this summary about? This is a plain language summary of a publication describing long-term results from the RESONATE-2 study with up to 8 years of follow-up. The original paper was published in Blood Advances in June 2022. [...]
2022 - 10.2217/fon-2022-0898
Future oncology (London, England), Vol. 18 Núm. 37 (january 2022)
|
|
|
5.
|
|
9 p, 442.2 KB |
B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy
/
Woyach, Jennifer A. (The Ohio State University Comprehensive Cancer Center, Columbus, Ohio) ;
Ghia, Paolo (Universita Vita-Salute San Raffaele, Milan, Italy) ;
Byrd, John C. (University of Cincinnati College of Medicine, Cincinnati, Ohio) ;
Ahn, Inhye E. (Laboratory of Lymphoid Malignancies, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland) ;
Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Brien, Susan M. (UC Irvine. Chao Family Comprehensive Cancer Center, Irvine, California) ;
Jones, Daniel (The Ohio State University Comprehensive Cancer Center, Irvine, California) ;
Cheung, Leo W.K. (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ;
Chong, Elizabeth (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ;
Kwei, Kevin (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ;
Dean, James P. (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ;
James, Dannelle F. (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ;
Wiestner, Adrian (Laboratory of Lymphoid Malignancies, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland)
Purpose: Acquired mutations in Bruton's tyrosine kinase (BTK) or phospholipase C-γ2 (PLCG2) genes are associated with clinical progressive disease (PD) in patients with chronic lymphocytic leukemia (CLL) treated with BTK inhibitors. [...]
2023 - 10.1158/1078-0432.CCR-22-3887
Clinical Cancer Research, Vol. 29 Núm. 16 (august 2023) , p. 3065-3073
|
|
|
6.
|
|
10 p, 685.7 KB |
Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia : the phase 2 CAPTIVATE study
/
Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Solman, Isabelle G. (Pharmacyclics LLC. an AbbVie Company) ;
Tam, Constantine S. (Monash University) ;
Grigg, Andrew (Austin Hospital) ;
Scarfò, Lydia (Università Vita Salute San Raffaele) ;
Kipps, Thomas J. (University of California. Moores Cancer Center) ;
Srinivasan, Srimathi (Janssen Research & Development) ;
Mali, Raghuveer Singh (Pharmacyclics LLC. an AbbVie Company) ;
Zhou, Cathy (Pharmacyclics LLC. an AbbVie Company) ;
Dean, James P. (Pharmacyclics LLC. an AbbVie Company) ;
Szafer Glusman, Edith (Pharmacyclics LLC. an AbbVie Company) ;
Choi, Michael (University of California)
We evaluated immune cell subsets in patients with chronic lymphocytic leukemia (CLL) who received first-line therapy with 3 cycles of ibrutinib then 13 cycles of ibrutinib plus venetoclax in the minimal residual disease (MRD) cohort of the CAPTIVATE study (NCT02910583). [...]
2023 - 10.1182/bloodadvances.2023010236
Blood advances, Vol. 7 Núm. 18 (26 2023) , p. 5294-5309
|
|
|
7.
|
|
9 p, 500.3 KB |
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL
/
Brown, J.R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Hillmen, Peter (St James Institute of Oncology) ;
O'Brien, S. (MD Anderson Cancer Center) ;
Barrientos, J.C. (Hofstra Northwell School of Medicine) ;
Reddy, N.M. (Vanderbilt-Ingram Cancer Center) ;
Coutre, S.E. (Stanford University) ;
Tam, Constantine S (Peter MacCallum Cancer Centre. St Vincent's Hospital) ;
Mulligan, S.P. (Royal North Shore Hospital) ;
Jaeger, U. (Medical University of Vienna) ;
Barr, P.M. (University of Rochester Cancer Center) ;
Furman, R.R. (New York Presbyterian Hospital) ;
Kipps, Thomas J (UCSD Moores Cancer Center) ;
Cymbalista, F. (Hôpital Avicenne) ;
Thornton, P. (Beaumont Hospital (Dublín, Irlanda)) ;
Caligaris-Cappio, F. (Universita Vita-Salute San Raffaele) ;
Delgado, J. (Hospital Clínic i Provincial de Barcelona) ;
Montillo, M. (Niguarda Hospital) ;
DeVos, S. (David Geffen School of Medicine at UCLA) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Pagel, J.M. (Swedish Cancer Institute) ;
Munir, Talha (St James Institute of Oncology) ;
Burger, Jan A (MD Anderson Cancer Center) ;
Chung, D. (Pharmacyclics LLC. AbbVie Company) ;
Lin, J. (Pharmacyclics LLC. AbbVie Company) ;
Gau, L. (Pharmacyclics LLC. AbbVie Company) ;
Chang, B. (Pharmacyclics LLC. AbbVie Company) ;
Cole, G. (Pharmacyclics LLC. AbbVie Company) ;
Hsu, E. (Pharmacyclics LLC. AbbVie Company) ;
James, D.F. (Pharmacyclics LLC. AbbVie Company) ;
Byrd, J.C. (Ohio State University) ;
Universitat Autònoma de Barcelona
In the phase 3 RESONATE study, ibrutinib demonstrated superior progression-free survival (PFS), overall survival (OS) and overall response rate (ORR) compared with ofatumumab in relapsed/refractory CLL patients with high-risk prognostic factors. [...]
2018 - 10.1038/leu.2017.175
Leukemia, Vol. 32 Núm. 1 (january 2018) , p. 83-91
|
|
|
8.
|
|
8 p, 393.1 KB |
Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry : An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project
/
Rawstron, Andy C. (St. James's Institute of Oncology) ;
Kreuzer, Karl-Anton (Universitätsklinikum Köln) ;
Soosapilla, Asha (Laverty Pathology) ;
Spacek, Martin (University Hospital) ;
Stehlikova, Olga (University Hospital Brno (República Txeca)) ;
Gambell, Peter (Peter MacCallum Cancer Centre) ;
McIver-Brown, Neil (Royal Bournemouth Hospital) ;
Villamor, Neus (Hospital Clínic i Provincial de Barcelona) ;
Psarra, Katherina (Evangelismos Hospital) ;
Arroz, Maria (C.H.L.O. Hospital S. Francisco Xavier) ;
Milani, Raffaella (Ospedale San Raffaele) ;
de la Serna, Javier (Hospital 12 de Octubre (Madrid)) ;
Cedena, M.Teresa (Hospital 12 de Octubre (Madrid)) ;
Jaksic, Ozren (Dubrava University Hospital) ;
Nomdedeu, Josep (Institut d'Investigació Biomèdica Sant Pau) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Rigolin, Gian Matteo (St. Anna University Hospital) ;
Cuneo, Antonio (St. Anna University Hospital) ;
Johansen, Preben (Aalborg Universitet) ;
Johnsen, Hans E. (Aalborg Universitet) ;
Rosenquist, Richard (Uppsala University) ;
Niemann, Carsten Utoft (Copenhagen University Hospital) ;
Kern, Wolfgang (MLL Munich Leukemia Laboratory) ;
Westerman, David (University Hospital Brno (República Txeca)) ;
Trneny, Marek (University Hospital) ;
Mulligan, Stephen (Laverty Pathology) ;
Doubek, Michael (Masaryk University) ;
Pospisilova, Sarka (Masaryk University) ;
Hillmen, Peter (St. James's Institute of Oncology) ;
Oscier, David (Royal Bournemouth Hospital) ;
Hallek, Michael (Universitätsklinikum Köln) ;
Ghia, Paolo (Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele) ;
Montserrat, Emili (Hospital Clínic i Provincial de Barcelona) ;
Universitat Autònoma de Barcelona
The diagnostic criteria for CLL rely on morphology and immunophenotype. Current approaches have limitations affecting reproducibility and there is no consensus on the role of new markers. The aim of this project was to identify reproducible criteria and consensus on markers recommended for the diagnosis of CLL. [...]
2018 - 10.1002/cyto.b.21595
Cytometry Part B - Clinical Cytometry, Vol. 94 Núm. 1 (january 2018) , p. 121-128
|
|
|
9.
|
|
9 p, 613.6 KB |
Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia : Primary analysis of the randomized, open-label mable study
/
Michallet, Anne-Sophie (CLCC Centre Léon Bérard) ;
Aktan, Melih (Istanbul University) ;
Hiddemann, Wolfgang (Ludwig- Maximilians University of Munich) ;
Ilhan, Osman (Ankara University School of Medicine) ;
Johansson, Peter (Uddevalla Hospital) ;
Laribi, Kamel (Centre Hospitalier du Mans) ;
Meddeb, Balkis (Aziza Othmana University Hospital) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Raposo, Joäo (Hospital de Santa Maria) ;
Schuh, Anna (Oxford University Hospitals) ;
Ünal, Ali (Erciyes University Medical School) ;
Widenius, Tom (Peijas Hospital) ;
Bernhardt, Alf (F. Hoffmann-La Roche Ltd) ;
Kellershohn, Kerstin (Roche Pharma AG) ;
Messeri, Dimitri (F. Hoffmann-La Roche Ltd) ;
Osborne, Stuart (F. Hoffmann-La Roche Ltd) ;
Leblond, Véronique (UPMC University) ;
Universitat Autònoma de Barcelona
MABLE investigated the efficacy and safety of rituximab plus bendamustine or rituximab plus chlorambucil in fludarabine-ineligible patients with chronic lymphocytic leukemia. Patients received rituximab plus bendamustine or rituximab plus chlorambucil every four weeks for six cycles. [...]
2018 - 10.3324/haematol.2017.170480
Haematologica, Vol. 103 Núm. 4 (23 2018) , p. 698-706
|
|
|
10.
|
|
9 p, 996.2 KB |
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia : Extended phase 3 results from RESONATE-2
/
Barr, Paul M. (University of Rochester) ;
Robak, Tadeusz (Medical University of Lodz) ;
Owen, Carolyn (Tom Baker Cancer Centre) ;
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ;
Bairey, Osnat (Sackler Faculty of Medicine. Tel Aviv University) ;
Bartlett, Nancy L. (Washington University School of Medicine) ;
Burger, Jan A. (University of Texas MD Anderson Cancer Center) ;
Hillmen, Peter (The Leeds Teaching Hospitals. St. James Institute of Oncology) ;
Coutre, Steven E (Stanford University School of Medicine) ;
Devereux, Stephen (Kings College Hospital) ;
Grosicki, Sebastian (School of Public Health. Silesian Medical University) ;
McCarthy, Helen (Royal Bournemouth Hospital) ;
Li, Jianyong (Jiangsu Province Hospital) ;
Simpson, David (North Shore Hospital) ;
Offner, Fritz (Universitair Ziekenhuis Gent) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Zhou, Cathy (Pharmacyclics. LLC an AbbVie Company) ;
Styles, Lori (Pharmacyclics. LLC an AbbVie Company) ;
James, Danelle (Pharmacyclics. LLC an AbbVie Company) ;
Kipps, Thomas J (University of California,San Diego. Moores Cancer Center) ;
Ghia, Paolo (Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele) ;
Universitat Autònoma de Barcelona
Results of RESONATE-2 (PCYC-1115/1116) supported approval of ibrutinib for first-line treatment of chronic lymphocytic Rleukemia. Extended analysis of RESONATE-2 was conducted to determine long-term efficacy and safety of ibrutinib in older patients with chronic lymphocytic leukemia. [...]
2018 - 10.3324/haematol.2018.192328
Haematologica, Vol. 103 Núm. 9 (31 2018) , p. 1502-1510
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
